Orygold

Orygold is a biotechnology company focused on the development of epigenetic therapies for the treatment of cancer. The company's primary focus is on the discovery and development of potent and selective inhibitors of Lysine-specific demethylase 1 (LSD1), an enzyme that plays a critical role in the regulation of gene expression and is often overexpressed in various malignancies. Orygold's lead programs aim to address high unmet needs in hematological cancers such as acute myeloid leukemia and solid tumors like small cell lung cancer. By modulating the epigenetic landscape, the company seeks to restore normal cellular differentiation and inhibit tumor growth.